logo
Twitter
Discord
Email
logo
logo
Celldex Therapeutics, Inc.NASDAQ - CLDX
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-06
2024-06-30 10-Q2024-06-302024-08-08
2024-03-31 10-Q2024-03-312024-05-06
2023-12-31 10-K2023-12-312024-02-26
2023-09-30 10-Q2023-09-302023-11-02
2023-06-30 10-Q2023-06-302023-08-08
2023-03-31 10-Q2023-03-312023-05-04
2022-12-31 10-K2022-12-312023-02-28
2022-09-30 10-Q2022-09-302022-11-09
2022-06-30 10-Q2022-06-302022-08-08
2022-03-31 10-Q2022-03-312022-05-05
2021-12-31 10-K2021-12-312022-02-28
2021-09-30 10-Q2021-09-302021-11-09
2021-06-30 10-Q2021-06-302021-08-05
2021-03-31 10-Q2021-03-312021-05-06
2020-12-31 10-K2020-12-312021-03-29
2020-09-30 10-Q2020-09-302020-11-05
2020-06-30 10-Q2020-06-302020-08-06
2020-03-31 10-Q2020-03-312020-05-06
2019-12-31 10-K2019-12-312020-03-26
1
2
3
20 / page
About
Name
Celldex Therapeutics, Inc.
Overview
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Show More
CEO
Mr. Anthony S. Marucci M.B.A.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
1986-05-15
Address
Perryville III Building, Suite 220 53 Frontage Road, Hampton, NJ, 08827, United States
Tel
908-200-7500
Website
https://www.celldex.com